South San Francisco, CA — May 29, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) in combination…Original Article
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
